Cryoport Reports First Quarter 2026 Financial Results

Cryoport (NASDAQ: CYRX) reported Q1 2026 revenue of $47.8 million, up 16% year-over-year, driven by strong performance in Life Sciences Services (18% growth) and Life Sciences Products (15% growth). Commercial CGT revenue grew 26% to $9.1 million, and the company supports a record 766 clinical trials and 21 approved therapies. The company raised full-year 2026 revenue guidance to $192-196 million and reported improved adjusted EBITDA from continuing operations.

05/04/2026, 4:05 PM • Benzinga

Biopharmaceutical Third Party Logistics (Distribution Management, Packaging & Labeling, Transportation, Warehousing) Market Research and Global Forecast Report 2026-2032

The biopharmaceutical third-party logistics market is expected to grow from $140.03 billion in 2025 to $384.23 billion by 2032, with a CAGR of 15.51%. Growth is driven by rising product complexity, regulatory scrutiny, cold chain integrity demands, and technological advancements in digital tracking and specialized handling for biologics and gene therapies.

04/09/2026, 4:49 AM • GlobeNewswire

Bio-Preservation Market to Reach US$ 44.45 Billion by 2035 | Cold Chain Expansion and Cell & Gene Therapy Commercialization Drive Growth Says Astute Analytica

The global bio-preservation market is projected to grow from USD 4.52 billion in 2025 to USD 44.45 billion by 2035 at a CAGR of 25.68%, driven by cell and gene therapy commercialization, cold chain expansion, and iPSC applications. North America commands 46% market share, with media consumables achieving 32% CAGR. Record FDA approvals (8 in 2024) and 23 anticipated filings in 2025 are accelerating commercial cold chain requirements.

02/11/2026, 1:40 PM • GlobeNewswire

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

Cryoport announced the launch of the MVE Fusion® 800 Series, a self-sustaining cryogenic freezer that eliminates the need for continuous liquid nitrogen supply. The compact system, recognized with the ISBER Outstanding New Product Award, is designed for space-constrained environments like medical research facilities, hospitals, and biorepositories, maintaining temperatures at or below -150°C.

02/11/2026, 8:30 AM • Benzinga

Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain

Cryoport Systems has become the first global supply chain solutions company to achieve ISO 21973 certification, demonstrating its leadership in ensuring safe and traceable transportation of cell and gene therapies.

10/30/2025, 8:30 AM • Benzinga

Cryoport Systems Expands Global Footprint with New Global Supply Chain Center in Paris, France

Cryoport Systems has launched a new 55,000-square-foot global supply chain center near Paris, France, expanding its network to support complex life sciences supply chain needs, including biologistics and bioservices.

10/01/2025, 8:30 AM • Benzinga

Clinical Trial Biorepository and Archiving Solutions Market Size Expected to Attain USD 9.69 Billion by 2034

The global clinical trial biorepository and archiving solutions market is projected to grow from USD 4.76 billion in 2025 to USD 9.69 billion by 2034, with a CAGR of 8.21%. North America dominates the market, while Asia Pacific is expected to experience the fastest growth, driven by advancements in biobanking technologies and increasing demand for personalized medicine.

08/19/2025, 11:00 AM • GlobeNewswire

CEO Jerrell Shelton Sells Some Shares of Cryoport (CYRX)

Cryoport CEO Jerrell Shelton exercised and sold 16,344 shares at $7.06 per share, retaining 928,763 shares. The company continues to face financial challenges with recent revenue drops and ongoing losses.

06/30/2025, 11:10 AM • The Motley Fool